Genscript Biotech Corp (HKEX: 1548) has announced a share placement agreement on September 11, 2026, under which the company will appoint placement agents to procure no fewer than six subscribers to acquire a total of 77.126 million new shares at an offer price of HK$30.50 each, according to a company filing.

The placement price represents a discount of approximately 4.7% to the closing price of HK$32.00 per share on the Hong Kong Stock Exchange on September 10, 2026, which was the last trading day prior to the agreement. It also reflects a discount of roughly 6.3% to the average closing price of HK$32.56 per share over the five consecutive trading days immediately preceding the date of the placement agreement.

The placement shares account for approximately 3.50% of the company's issued share capital as of the announcement date, and roughly 3.38% of the enlarged issued share capital following the allotment and issuance of the placement shares, assuming no change in the company's issued share capital from the announcement date to the settlement date.

Assuming all placement shares are fully subscribed, the total gross proceeds from the placement are expected to reach approximately HK$2.352 billion. After deducting placement commissions and other related expenses, including professional fees, the net proceeds are estimated to be around HK$2.327 billion, equivalent to an estimated net issue price of approximately HK$30.17 per placement share. No subscriber is expected to become a substantial shareholder immediately following the completion of the placement.

The company currently intends to allocate the net proceeds from the placement as follows: approximately 70% for expanding the group's AIDD platform capacity and infrastructure, including automated high-throughput wet laboratory facilities, related equipment, and laboratory upgrades; approximately 20% for research and development related to the AIDD platform, digital workflow integration, and global business expansion; and the remaining approximately 10% for general corporate purposes and working capital. The specific allocation of proceeds may be adjusted by the board of directors or its authorized personnel based on the company's or the group's operational conditions and actual needs.